SciClone Pharmaceuticals (Holdings) Limited
HKEX:6600.HK
18.72 (HKD) • At close June 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2020 Q4 | 2020 Q3 | 2019 Q4 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 776.142 | 776.142 | 801.666 | 801.666 | 637.305 | 637.305 | 737.536 | 334.389 | 423.191 | 417.297 |
| Cost of Revenue
| 195.399 | 195.399 | 204.308 | 204.308 | 169.128 | 169.128 | 170.471 | 82.043 | 110.879 | 100.396 |
| Gross Profit
| 580.743 | 580.743 | 597.358 | 597.358 | 468.177 | 468.177 | 567.066 | 252.346 | 312.312 | 316.901 |
| Gross Profit Ratio
| 0.748 | 0.748 | 0.745 | 0.745 | 0.735 | 0.735 | 0.769 | 0.755 | 0.738 | 0.759 |
| Reseach & Development Expenses
| 48.977 | 48.977 | 36.363 | 36.363 | 36.913 | 36.913 | 25.017 | 26.703 | 18.75 | 28.318 |
| General & Administrative Expenses
| 47.299 | 47.299 | 31.349 | 31.349 | 35.269 | 35.269 | 27.499 | 158.351 | -11.696 | 11.063 |
| Selling & Marketing Expenses
| 193.132 | 193.132 | 163.274 | 163.274 | 174.107 | 174.107 | 139.769 | 157.959 | 128.472 | 144.323 |
| SG&A
| 240.43 | 240.43 | 194.623 | 194.623 | 209.376 | 209.376 | 167.268 | 316.31 | 116.776 | 155.386 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | -69.72 | 51.85 | 15.23 |
| Operating Expenses
| 325.53 | 325.53 | 250.017 | 250.017 | 286.467 | 286.467 | 273.474 | 273.293 | 187.376 | 198.934 |
| Operating Income
| 302.77 | 302.77 | 376.073 | 376.073 | 224.304 | 224.304 | 378.621 | 71.91 | 113.92 | 130.374 |
| Operating Income Ratio
| 0.39 | 0.39 | 0.469 | 0.469 | 0.352 | 0.352 | 0.513 | 0.215 | 0.269 | 0.312 |
| Total Other Income Expenses Net
| -43.19 | -43.19 | -26.954 | -26.954 | -43.491 | -43.491 | -89.394 | -9.922 | -12.088 | 3.872 |
| Income Before Tax
| 259.58 | 259.58 | 349.119 | 349.119 | 180.813 | 180.813 | 289.227 | 61.988 | 101.832 | 134.246 |
| Income Before Tax Ratio
| 0.334 | 0.334 | 0.435 | 0.435 | 0.284 | 0.284 | 0.392 | 0.185 | 0.241 | 0.322 |
| Income Tax Expense
| 13.721 | 13.721 | 34.027 | 34.027 | 19.235 | 19.235 | 23.128 | -1.951 | 9.186 | 6.82 |
| Net Income
| 245.86 | 245.86 | 315.092 | 315.092 | 161.579 | 161.579 | 266.099 | 63.939 | 92.646 | 127.426 |
| Net Income Ratio
| 0.317 | 0.317 | 0.393 | 0.393 | 0.254 | 0.254 | 0.361 | 0.191 | 0.219 | 0.305 |
| EPS
| 0.38 | 0.38 | 0.48 | 0.48 | 0.23 | 0.23 | 0.38 | 0.094 | 0.14 | 0.19 |
| EPS Diluted
| 0.38 | 0.38 | 0.48 | 0.48 | 0.23 | 0.23 | 0.38 | 0.094 | 0.14 | 0.19 |
| EBITDA
| 332.948 | 332.948 | 411.106 | 411.106 | 251.243 | 251.243 | 403.339 | 88.266 | 161.46 | 141.313 |
| EBITDA Ratio
| 0.429 | 0.429 | 0.513 | 0.513 | 0.394 | 0.394 | 0.547 | 0.264 | 0.382 | 0.339 |